Full Press Release Details
CGuardTM Highlighted at the Late-Breaking Clinical Trial Session at the EuroPCR 2016 Conference
BOSTON, MA - May 17, 2016
- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention
systems (EPS), neurovascular devices and thrombus management technologies, today announced that CGuardTM EPS reported
positive results in PARADIGM-101, an investigator led clinical evaluation of the system for routine use in 101 consecutive, increased
risk patients undergoing carotid artery stenting. Principle investigator Prof. Piotr Musialek presented the results of the study
at the EuroPCR 2016 Late-Breaking Clinical Trial Session in Paris, France.
PARADIGM-101 is Prof. Musialek's
clinical evaluation of the safety and periprocedural and 30 day clinical efficacy of routine use of the CGuardTM system
in unselected carotid stenosis patients, building upon the earlier PARADIGM study. The trial also assessed the CGuardTM
system's ability to minimize vessel narrowing after carotid stenting.
In the presentation, Prospective evaluation
of all-comer percutaneous carotid revascularisation In symptomatic and increased-risk asymptomatic carotid artery stenosis using
the MicroNet-covered embolic prevention stent system in 101 consecutive patients: PARADIGM-101, Prof. Musialek's key
Prof. Musialek commented, "PARADIGM-101
supports the use of CGuardTM in a high risk, all comer population of patients with carotid artery stenosis, building
upon the safety of the MicroNetTM covered CGuardTM as a novel, therapeutic stent platform. This latest data
indicates that routine use of CGuardTM may prevent cerebral events - such as strokes - by holding plaque against
the vessel wall, preventing emboli from being released into the blood stream." Prof. Musialek concluded, "On the basis
of PARADIGM findings, CGuard may open a safe door for endovascular management to more than 90% of all-comer patients with carotid
stenosis who require interventional treatment."
EuroPCR is a leading course in interventional
cardiovascular medicine, with over 12,000 attendees.
For more information about InspireMD and
its offerings, visit www.inspiremd.com.
PARADIGM is an investigator-initiated Prospective
evaluation of All-comer peRcutaneous cArotiD revascularization In symptomatic and increased-risk
asymptomatic carotid artery stenosis, using CGuard Mesh-covered embolic prevention stent system. At EuroPCR
2015, Dr. Musialek summarized the results of his PARADIGM evaluation of 71 CGuardTM procedures in unselected all-comer
patients: 1) stent system success and procedure success rate of 100%; 2) periprocedural complications of 0%, and remained at 0%
at 30 days; and 3) no MACNE occurred periprocedurally or at 30 days, by operator-independent neurologist and non-invasive cardiologist
The proprietary CGuard Embolic Prevention
System (EPS) uses the same MicroNet technology featured on the MGuard and MGuard Prime coronary Embolic Protection
Systems. The CGuard EPS is designed to prevent peri-procedural and late embolization by trapping potential emboli against
the arterial wall while maintaining excellent perfusion to the external carotid artery and branch vessels.
MicroNet is a bio-stable mesh woven
from a single strand of 20 micron Polyethylene Terephthalate (PET).
CGuard EPS is CE Marked and not
approved for sale in the U.S. by the U.S. Food and Drug Administration at this time.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary
MGuard with MicroNetTM technology to make its products the industry standard for embolic protection and to provide
a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow
and major adverse cardiac events.
InspireMD intends to pursue applications
of this MicroNet technology in coronary, carotid (CGuardTM), neurovascular, and peripheral artery procedures. InspireMD's
common stock is quoted on the NYSE MKT under the ticker symbol NSPR.
Forward-looking Statements
This press release contains "forward-looking
statements." Such statements may be preceded by the words "intends," "may," "will," "plans,"
"expects," "anticipates," "projects," "predicts," "estimates," "aims,"
"believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees
of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many
of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks
and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results
or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv)
intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi)
product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient
or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain
and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory
reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product
components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that
such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign
jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and
costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about
the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings
with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports
on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.
The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future
events or otherwise.
Chief Financial Officer
Email: craigs@inspiremd.com
Phone: (212) 554-5482